Baum Hedlund attorney, Karen Barth Menzies Testified at the FDA Psychopharmacologic Drugs Advisory Committee meeting on December 13, 2006 concerning the FDA’s Review of Suicidality Data in Adult Antidepressant Studies

Karen Barth Menzies Written Comments Submitted to the FDA PDAC

December 11, 2006, Washington, D.C. - - Baum Hedlund attorney, Karen Barth Menzies will testify before the FDA’s Psychopharmacologic Drugs Advisory Committee meeting on December 13, 2006. Ms. Menzies will be speaking from her perspective as an attorney who has represented more than one hundred families whose loved ones have committed suicide and individuals who have attempted suicide while taking an SSRI antidepressant.

Ms. Menzies submitted a statement to the FDA’s advisory committee on December 1, 2006 detailing the long history of drug manufacturer and FDA failure to warn of the risk of antidepressant-induced suicidality.

In her testimony before the PDAC, Ms. Menzies will respond to the FDA’s meta-analysis of suicidality data released last week.

Karen will also be one of the speakers at two press conferences sponsored by Alliance for Human Research Protection http://www.ahrp.org/ and WoodyMatters.com, taking place the day before the FDA hearings, on December 12, along with a number of experts (David Healy, MD, Joseph Glenmullen, MD, John Abramson, MD, David Cohen, Ph. D, Stefan Kruswewski, MD) who will provide a critical review of the FDA’s analysis.